Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.
Core Products and Clinical Pipeline:
- HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
- CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
- Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
- Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
- Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.
Recent Achievements and Financial Highlights:
- Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
- As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
- For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.
Strategic Partnerships:
Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.
For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.
Dynavax Technologies (DVAX) reported its financial results for Q4 and full year 2020, highlighting a net loss of $15.5 million in Q4, improved from a loss of $36.8 million in Q4 2019. Total revenues rose to $46.6 million for 2020, up from $35.2 million in 2019. HEPLISAV-B product revenue reached $36 million, a 4% increase year-over-year. The company anticipates significant revenue from collaborations utilizing its adjuvant CpG 1018, potentially generating up to $230 million in 2021. Cash reserves stood at $165 million at the end of 2020.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that the European Commission has granted marketing authorization for HEPLISAV B, a two-dose hepatitis B vaccine for adults aged 18 and older. This approval follows a positive opinion from the European Medicines Agency based on favorable safety and immunogenicity results from three Phase 3 trials. Hepatitis B is highly infectious, affecting over 250 million globally. With a higher seroprotection rate than traditional vaccines, HEPLISAV B aims to improve compliance and is expected to launch in Europe later this year.
Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company, announced that CEO Ryan Spencer will present at the Cowen 41st Annual Health Care Conference on March 1, 2021, at 3:20 p.m. E.T. The presentation will be available via webcast on the Company’s investors website. Dynavax is known for its vaccine development, particularly HEPLISAV-B®, approved for hepatitis B prevention in adults, and is advancing CpG 1018 as a vaccine adjuvant for various diseases.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced it will report its fourth quarter and full year 2020 financial results on February 25, 2021, after market close. The company will host a conference call at 4:30 p.m. ET the same day. Investors can access the live audio webcast on the company's website. Dynavax focuses on developing vaccines and has commercialized HEPLISAV-B®, a hepatitis B vaccine. The company is also advancing CpG 1018 as a vaccine adjuvant, collaborating on vaccines for COVID-19, pertussis, and universal influenza.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the appointment of Dong Yu, Ph.D., as Senior Vice President of Vaccine Research on February 8, 2021. Dr. Yu, with over 15 years of experience in vaccine research, will lead the company's vaccine programs and technology platforms. He previously held significant roles at GSK Vaccines and Novartis Vaccines. As part of his employment, Dr. Yu received a stock option grant for 225,000 shares at an exercise price of $11.18. This appointment aims to bolster Dynavax's growth as a global vaccine leader.
Dynavax Technologies Corporation (Nasdaq: DVAX) recently announced the grant of nonstatutory stock options for 7,500 shares of common stock to a new employee. The options, awarded on February 1, 2021, have an exercise price of $10.27 per share, reflecting the closing stock price on the grant date. These options vest over three years, starting with one-third vesting after one year. This move aligns with Nasdaq Listing Rule 5635(c)(4) and supports the company's strategy to attract talent as it advances its vaccine development initiatives.
Dynavax Technologies Corporation (Nasdaq: DVAX) and Serum Institute of India (SIIPL) announced the initiation of a Phase 1 clinical trial for an improved Tdap booster vaccine candidate, adjuvanted with CpG 1018. The trial aims to address the challenges associated with current acellular pertussis vaccines, which have seen a rise in pertussis cases in industrialized nations. The clinical trial will evaluate safety and immunogenicity in healthy volunteers aged 10 to 22. Results are anticipated by Q4 2021, with Dynavax holding exclusive commercialization rights globally, excluding India.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced that the UK Government ordered an additional 40 million doses of Valneva's SARS-CoV-2 vaccine candidate, VLA2001. This triggers the reservation of Dynavax's adjuvant, CpG 1018, for production support. Dynavax expects to generate up to $230 million in revenue from this deal in 2021, contingent on successful material delivery. This partnership aims to enhance vaccine development, following a prior agreement for up to 190 million doses over five years.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to supply its CpG 1018 adjuvant for COVID-19 vaccines. CEPI will provide up to $99 million in funding through a forgivable loan to support the manufacturing of CpG 1018. This agreement aims to enhance vaccine efficacy and ensure equitable access globally. The stockpiled adjuvant will be available for CEPI grantees, with reimbursement obligations tied to sales. This collaboration underscores CpG 1018's potential role in addressing the pandemic.
Clover Biopharmaceuticals and Dynavax Technologies (DVAX) announced plans to initiate a global Phase 2/3 efficacy trial for the S-Trimer COVID-19 vaccine candidate in the first half of 2021. This trial, supported by CEPI, aims for interim efficacy results mid-2021. Clover's vaccine showed promising results in Phase 1, generating high neutralizing antibodies with a favorable safety profile. Clover aims to produce up to 1 billion doses annually. The partnership with GSK evaluating an adjuvant has been discontinued, but both companies remain committed to combating the pandemic.
FAQ
What is the current stock price of Dynavax Technologies Corporation (DVAX)?
What is the market cap of Dynavax Technologies Corporation (DVAX)?
What is Dynavax Technologies Corporation known for?
What are the key products of Dynavax?
What is HEPLISAV-B®?
What is the significance of the CpG 1018® adjuvant?
Who are Dynavax's key partners?
What are the recent financial highlights of Dynavax?
What is the clinical pipeline focus of Dynavax?
How does Dynavax plan to sustain its growth?
How can investors get updates on Dynavax?
What are the most common adverse reactions to HEPLISAV-B?
